New Delhi, November 3: The Technical Advisory Group (TAG), an independent advisory committee of the World Health Organisation (WHO), has recommended Emergency Use Listing (EUL) status for Bharat Biotech COVID-19 vaccine Covaxin, sources in the know of the development said.

The WHO is in the process of evaluating Covaxin's clinical trial data for use of EUL. Also Read | Cryptocurrency Investments In India: Know How Much Tax Does India Charge For Profits on Digital Currency.

The TAG on October 26 had sought "additional clarifications" from the company for Covaxin to conduct a final "risk-benefit assessment" for Emergency Use Listing of the vaccine. "The Technical Advisory Group of WHO has recommended Emergency Use Listing status for Covaxin," a source told PTI. Also Read | COVID-19 Vaccine Update: Bharat Biotech’s COVAXIN Gets Shelf Life Extension Up to 12 Months.

The TAG-EUL is an independent advisory group that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure.

Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant. In June, the company said it concluded the final analysis of Covaxin efficacy from Phase 3 trials.

Bharat Biotech's Covaxin and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)